![Charles Newton](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Charles Newton
Direktor/Vorstandsmitglied bei
COHERUS ONCOLOGY, INC.
Vermögen: 603 074 $ am 31.05.2026
Profil
Charles W.
Newton is currently an Independent Director at Coherus Oncology, Inc. since 2022, an Independent Director at Novavax, Inc. starting in 2025, and a Director at Keros Therapeutics, Inc. starting in 2026.
Former positions include Independent Director at 2seventy Bio, Inc. from 2024 to 2025, Managing Director at BofA Securities, Inc., Managing Director at Credit Suisse Group AG from 2010 to 2015, Independent Director at Carmot Therapeutics, Inc. from 2023 to 2024, MD & Head-Western Region Healthcare Investment at Morgan Stanley from 1996 to 2010, Chief Financial & Accounting Officer at Lyell Immunopharma, Inc. from 2021 to 2025, and MD & Head-Healthcare Investment Banking at Bank of America Corp.
from 2015 to 2021.
Education includes undergraduate studies at Miami University and an MBA from Tuck School of Business at Dartmouth.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 21.08.2025 | 25’306 ( 0.11% ) | 438 553 $ | 31.05.2026 | |
NOVAVAX, INC. 0.01% | 25.04.2026 | 9’520 ( 0.01% ) | 104 434 $ | 31.05.2026 |
| 05.06.2026 | 30’000 ( 0.02% ) | 47 700 $ | 31.05.2026 | |
| 31.03.2026 | 1’101 ( 0.01% ) | 12 386 $ | 31.05.2026 |
Aktive Positionen von Charles Newton
| Unternehmen | Position | Beginn |
|---|---|---|
| COHERUS ONCOLOGY, INC. | Direktor/Vorstandsmitglied | 05.05.2022 |
| NOVAVAX, INC. | Direktor/Vorstandsmitglied | 25.04.2025 |
| KEROS THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 09.03.2026 |
Ehemalige bekannte Positionen von Charles Newton
| Unternehmen | Position | Ende |
|---|---|---|
| LYELL IMMUNOPHARMA, INC. | Finanzdirektor/CFO | 21.10.2025 |
| 2SEVENTY BIO, INC. | Direktor/Vorstandsmitglied | 13.05.2025 |
Carmot Therapeutics, Inc.
 Carmot Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company that develops drugs for inflammatory, metabolic and neurological diseases | Direktor/Vorstandsmitglied | 01.01.2024 |
| BANK OF AMERICA CORPORATION | Corporate Officer/Principal | 01.02.2021 |
Credit Suisse Group AG /US/
 Credit Suisse Group AG /US/ Financial ConglomeratesFinance Provides financial services | Vorstandsvorsitzender | 01.11.2015 |
Ausbildung von Charles Newton
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
94
Beziehungen ersten Grades
12
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 12 |
|---|---|
Bank of America Corp.
 Bank of America Corp. Major BanksFinance Operates as a bank holding company whose subsidiaries provides consumer and global banking, markets brokerage & wealth and investment management services | Finance |
Morgan Stanley
 Morgan Stanley Investment ManagersFinance Provides wealth and asset management, trading & investment banking services | Finance |
Novavax, Inc.
 Novavax, Inc. BiotechnologyHealth Technology Engages in development of novel recombinant vaccines | Health Technology |
Miami University
 Miami University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Carmot Therapeutics, Inc.
Carmot Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company that develops drugs for inflammatory, metabolic and neurological diseases | Health Technology |
Tuck School of Business at Dartmouth
 Tuck School of Business at Dartmouth Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Coherus BioSciences, Inc.
 Coherus BioSciences, Inc. Pharmaceuticals: MajorHealth Technology Operates as a commercial-stage biopharmaceutical company that engages in research, development and commercialization of immunotherapies to treat cancer | Health Technology |
Keros Therapeutics, Inc.
 Keros Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops therapeutics for muscle diseases | Health Technology |
BofA Securities, Inc.
 BofA Securities, Inc. Investment Banks/BrokersFinance Provides brokerage services | Finance |
Credit Suisse Group AG /US/
Credit Suisse Group AG /US/ Financial ConglomeratesFinance Provides financial services | Finance |
Lyell Immunopharma, Inc.
 Lyell Immunopharma, Inc. BiotechnologyHealth Technology Develops cell-based immunotherapies for human diseases | Health Technology |
2seventy Bio, Inc.
 2seventy Bio, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceuticals for the treatment of cancer and genetic diseases | Health Technology |
